8 completed, 3 terminated, 1 active not recruiting, 1 recruiting. 9 Phase 2, 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 4, Terminated 3, Active not recruiting 1, Recruiting 1 |
| Phase 1 | 8 | Completed 6, Recruiting 1, Terminated 1 |
Follow lirilumab: new trials by email Literature Review of lirilumab trials Research Report on lirilumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Nivolumab, Nivolumab/Lirilumab - Bladder Cancer | Phase 1 | Completed | PrECOG, LLC. | 43 | 2019-03-22 | 2024-09-19 |
| A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208) Epacadostat, Nivolumab, Ipilimumab - Solid Tumors | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 11 | 2018-03-21 | 2022-02-28 |
| Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN Nivolumab, Lirilumab - Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 29 | 2018-03-15 | 2025-06-18 |
| A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors Lirilumab, Nivolumab, Ipilimumab - Advanced Cancer | Phase 1 | Completed | Bristol-Myers Squibb | 10 | 2017-07-14 | 2022-03-10 |
| European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors Ribociclib, Topotecan, Temozolomide - Pediatric Cancer | Phase 1 / Phase 2 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 472 | 2016-08-03 | 2026-07-10 |
| Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS) Lirilumab, Nivolumab, Azacitidine - Leukemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 10 | 2016-03-21 | 2020-01-14 |
| Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients Lirilumab, Rituximab - Leukemia, Chronic Lymphocytic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 7 | 2015-06-23 | 2020-05-28 |
| Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia Azacitidine, Lirilumab - Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Terminated | M.D. Anderson Cancer Center | 36 | 2015-04-20 | 2019-09-24 |
| A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma Elotuzumab, Lirilumab, Urelumab - Multiple Myeloma | Phase 1 | Completed | Bristol-Myers Squibb | 44 | 2014-12-09 | 2017-11-01 |
| Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor Lirilumab, Ipilimumab - CANCER, NOS | Phase 1 | Completed | Bristol-Myers Squibb | 22 | 2012-12-01 | 2015-07-22 |
| A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors Lirilumab, Nivolumab, Ipilimumab - CANCER,NOS | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 337 | 2012-10-07 | 2023-02-02 |
| Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR) IPH2102 at 0.1 mg/kg, IPH2102 at 1 mg/kg, Placebo (normal saline solution) - Acute Myeloid Leukemia | Phase 2 | Completed | Innate Pharma | 152 | 2012-10-01 | 2019-02-08 |
| An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma Nivolumab, Ipilimumab, Lirilumab - Non-Hodgkin's Lymphoma, Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 320 | 2012-08-02 | 2025-10-22 |
Neoplasms (3) · Leukemia (2) · Leukemia, Myeloid, Acute (2) · Multiple Myeloma (2) · Squamous Cell Carcinoma of Head and Neck (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Squamous Cell (1) · Hodgkin Disease (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Lymphoid (1) · Lymphoma, Non-Hodgkin (1) · Melanoma (1) · Myelodysplastic Syndromes (1) · Recurrence (1)
Bristol-Myers Squibb (5) · M.D. Anderson Cancer Center (3) · Dana-Farber Cancer Institute (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Incyte Corporation (1) · Innate Pharma (1) · PrECOG, LLC. (1)
United States (10) · France (4) · Italy (3) · Spain (3) · Belgium (1) · Canada (1) · Denmark (1) · Greece (1) · Japan (1) · Netherlands (1) · Poland (1) · Switzerland (1) · United Kingdom (1)
Birgit Geoerger, MD (1) · Glenn J. Hanna, MD (1) · Guillermo Garcia-Manero, MD (1) · Naval Daver (1) · Nitin Jain, MBBS (1) · Norbert Ifrah, MD (1) · Norbert Vey, MD (1) · Petros Grivas, MD, PhD (1)
PMID 25482239, PMID 27269947, PMID 30001986, PMID 31538815, PMID 33892407, PMID 34347542, PMID 34543871, PMID 35292802, PMID 38155060, PMID 41838385, PMID 42686334
2016 (1), 2017 (1), 2018 (1), P30CA016672 (1)